Tvardi Therapeutics, Inc.
TVRDHealthcare|Biotechnology|US
$0.96
+0.09 (+10.79%)
DCF Value
$2.25
Tangible Book / Share
$0.86
Cash / Share
$1.68
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05440708 A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma | P1P2 | Recruiting | 193 | Open-label | TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab |
| NCT06141031 Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer | P1 | Recruiting | 24 | Open-label | TTI-101 |
| NCT05668949 Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC) | Head and Neck Squamous Cell Carcinoma | P1P2 | Withdrawn | — | RCT, Open-label | TTI-101, Pembrolizumab |
| NCT05671835 Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | P2 | Completed | 100 | RCT, Double-blind | TTI-101, Placebo |
| NCT05384119 Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer | Breast Cancer | P1 | Terminated | 6 | Open-label | TTI-101, Palbociclib, Aromatase inhibitor (AI), fulvestrant, ribociclib |
| NCT03195699 Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | Breast Cancer, Head and Neck Squamous Cell Carcinoma | P1 | Completed | 64 | Open-label | TTI-101, TTI-101 |
| NCT05845307 Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of Head and Neck | Early P1 | Withdrawn | — | Open-label | Control Group, TTI-101 |